Calcium lactate compositions and methods of use
AssigneeMetimedi Pharmaceuticals Co., Ltd.
InventorsChong Hwan CHANG, Keun-Yeong Jeong
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.
Claims8
An enteric coated oral composition comprising:
- a therapeutically effective amount of calcium lactate;
- and
- a polysaccharide,
- wherein the enteric coated oral composition is formulated for rapid disintegration in the intestinal environment, and the oral composition is coated with a pharmaceutically acceptable enteric coating;
- the enteric coating comprises a hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), shellac, polymer of methacrylic acid and an ester thereof, or combinations thereof, and
- the weight ratio of the calcium lactate and the enteric coating is from 10:0.5 to 1:1.5.
A pharmaceutical oral composition comprising the enteric coated oral composition of claim 1. The pharmaceutical oral composition of claim 6, further comprising an anticancer agent.
The pharmaceutical oral composition of claim 7, wherein the anticancer agent is selected from the group consisting of Imatinib, 5-Fluorouracil, lrinotecan, Sunitinib, Oxaliplatin, Paclitaxel, Lapatinib, Trastuzumab, Gefitinib, Erlotinib, Methotrexate, Carboplatin, Docetaxel, Everolimus, Sorafenib, a carbonic anhydrase inhibitor, and a monocarboxylate transporter inhibitor.
Dependencies are inferred from the claim text.